Abnova (Taiwan) Corporation (4133.TW)
- Previous Close
28.85 - Open
28.85 - Bid 28.45 x --
- Ask 28.75 x --
- Day's Range
28.30 - 28.85 - 52 Week Range
21.70 - 36.30 - Volume
67,630 - Avg. Volume
150,339 - Market Cap (intraday)
1.732B - Beta (5Y Monthly) 0.36
- PE Ratio (TTM)
28.04 - EPS (TTM)
1.02 - Earnings Date --
- Forward Dividend & Yield 0.72 (2.48%)
- Ex-Dividend Date Jun 6, 2024
- 1y Target Est
--
Abnova (Taiwan) Corporation manufactures and sells various recombinant proteins and antibodies. The company's products portfolio includes SARS-CoV/CoV-2 DNA, RNA, proteins/peptides, lysates/slides, Ab pairs/kits, Ab arrays, polyclinic antibody, beads/dyes, in situ hybridization products, systems, and automations. It also offers MaxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and circulating rare cell antibodies. In addition, the company provides integrated solutions and services, including gene synthesis and cytogenetics; peptide services, protein expression, and conjugations; antibody production; and assay development services. It serves academic, research institutions, and pharmaceutical factories. Abnova (Taiwan) Corporation was founded in 2002 and is headquartered in Taipei, Taiwan.
www.abnova.comRecent News: 4133.TW
View MorePerformance Overview: 4133.TW
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4133.TW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4133.TW
View MoreValuation Measures
Market Cap
1.73B
Enterprise Value
1.31B
Trailing P/E
28.04
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.88
Price/Book (mrq)
1.32
Enterprise Value/Revenue
3.68
Enterprise Value/EBITDA
12.66
Financial Highlights
Profitability and Income Statement
Profit Margin
17.34%
Return on Assets (ttm)
1.55%
Return on Equity (ttm)
4.75%
Revenue (ttm)
355.26M
Net Income Avi to Common (ttm)
61.61M
Diluted EPS (ttm)
1.02
Balance Sheet and Cash Flow
Total Cash (mrq)
448.54M
Total Debt/Equity (mrq)
1.87%
Levered Free Cash Flow (ttm)
22.91M